Biomarkers for pancreatic cancer and diagnostic methods
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 21, 2014
Grant Date -
Oct 20, 2011
app pub date -
Nov 22, 2010
filing date -
Apr 15, 2005
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Methods and related kits for differentiating pancreatic cancer from a benign pancreatic disease. The method includes assaying a patient biological sample for a total level of CA 19-9 antigen and for a glycan level in specific mucin(s), and comparing the total level of CA 19-9 antigen and the glycan level in the specific mucin(s) to statistically validated thresholds, wherein a different level of total CA 19-9 antigen in the patient biological sample as compared to a statistically validated threshold and a different level of glycan level in the specific mucin(s) as compared to statistically validated thresholds indicate pancreatic cancer in the patient rather than a benign pancreatic disease.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully